Mitarbeit an Studien - NP-MHH / consent reading

 

 

Standardized diagnostic workup and histopathological report on all renal transplant biopsies being taken within the IFB-Tx program following a uniquely developed protocol including a complete actual Banff classification (executive nephropathologist since 04/2014)

Clinical Protocol IM103116: Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression. Study Phase: 3b – (three renal transplant centres

Clinical Protocol:  HGS1006-C1121 (Human Genome Sciences): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis. Phase: 3

Clinical Protocol: QRK306: A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant. Phase 3

Clinical Protocol: 200710602 „RIACT”: Double blind controlled trial on Rituximab/MabThera® in comparison to steroid alone in acute cellular rejection in renal transplants

Controlled trial (CL011_168): Evaluation of Avacopan in C3 glomerulopathy

APL2-C3G-310: A phase 3, randomized, placebo-controlled, double-blinded, multicenter study to evaluate the efficacy and safety of pegcetacoplan in patients with C3 glomerulopathy or immune-complex membranoproliferativ glomerulonephritis

VKTX01 der Firma Vitaeris (CSL300_3001 - site 450)

ALXN2050-NEPH-201 A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (lgAN)

Clinical Protocol: D3461C00007: Multicentre, randomised, double-blind, placebo-controlled, Phase 2 Study Evaluation of the efficacy and safety of Anifrolumab in adult subjects with active proliferative Lupus nephritis

ALE.F02.03A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Rapidly Progressive Glomerulonephritis

Clinical Protocol: Mass spectrometry (DFG): Non-invasive diagnosis of acute rejection in renal transplant patients using mass spectrometry of urine samples. A multicentre diagnostic phase 3 trial

Clinical Protocol: 3xBIOS² study: Biomarkers of renal graft injuries in kidney allograft recipients (BIOMARGIN)

CCFZ533X2201: A 12-months randomized, multiple dose, open-label, study evaluating safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and efficacy of an anti-CD40 monoclonal antibody, CFZ533, in combination with mycophenolate mofetil (MMF) and corticosteroids (CS), with and witout tacrolimus (Tac), in de novo renal transplant recipients. 2016-2017

 

 “Kidney Doc”: Prospective multicentre study aiming at standardizing and harmonizing the nationwide anti-rejection strategy/therapy in renal transplant patients being biopsied. Study started with 2 centres: University of Schleswig-Holstein, Campus Kiel, Clinic for Nephrology and Hypertension and Department of Nephrology, Clinics Rechts der Isar, Technical University of Munich.

CRAD001A2429: A 24 months, multi-center, open-label, randomized, controlled trial to investigate efficacy, safety and evolution of cardiovascular parameters in de novo renal transplant recipients after early calcineurin inhibitor to everolimus conversion. 2011-2015 (UK Essen)

„A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, SAR442970, and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)“ ACT18064